ACLFAcute-on-Chronic Liver Failure
ACLFAdult Congregate Living Facility (retirement home)
ACLFAmerican Constitutional Law Foundation
ACLFAssisted Care Living Facility
ACLFAssociation des Cytogénéticiens de Langue Française (French: French Language Cytogeneticists Association)
ACLFAccess Control List Facility
ACLFAustin City Limits Festival (Austin, Texas)
ACLFAdult Care Living Facility
ACLFAssociation des Chercheurs en Littératures Francophones (French: Association of Researchers in Francophone Literature; est. 2001)
ACLFAustralian Coupe Liberation Front
ACLFAutomatic Channel Locking Filter (Digital Lightwave)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
1998 WL 221384; Petitioner's Reply to Brief in Opposition, ACLF,
(187) An initiative's actual entry onto the ballot embodies the same features that led the Meyer and ACLF Courts to label the attendant petitioning processes "core political speech" and apply strict scrutiny to regulations on petition circulation.
Roger Brocklehurst, director of the Local Investment Fund, said the ACLF was the largest regional loan fund to date.
Plaintiff argued that the suit against the ACLF was for negligent failure to transfer, whereas its suit against the two home health agencies was for negligent health care; the legal elements of damages from each being different.
ACLF monthly rents start at $1,090, all meals included.
Promethera is pioneering the use of liver-derived stem cells for the treatment of ACLF and non-alcoholic fatty liver disease (NASH).
Some scoring systems efficiently assess the severity and mortality of ACLF, such as SOFA score [8], MELD [9], and King's College Criteria [10].
Many studies demonstrated that Treg and Th17 cells were tightly associated with many human diseases, including the ACLF [13, 14].
The scope of the relationship includes R&D support for Promethera's HepaStem development program in acute on chronic liver failure (ACLF), non-alcoholic steatohepatitis (NASH) and urea cycle disorder (UCD) in selected Asian markets.
The product candidate is currently being evaluated in a Phase 2a clinical trial in the indication ACLF with safety and initial efficacy results expected to be available early 2019.